Benralizumab: A Major Breakthrough in Asthma Treatment
A major breakthrough in asthma treatment has been achieved through the use of Benralizumab, which researchers are calling a “game-changer.” Benralizumab, the first new treatment for asthma attacks and chronic obstructive pulmonary disease (COPD) in 50 years, was initially approved by US and EU regulators in 2017. It was specifically designed to treat eosinophilic asthma, a severe form of the condition linked to lung inflammation caused by certain white blood cells.
How Benralizumab Works
Benralizumab works by targeting eosinophils, a type of white blood cell linked to lung inflammation and damage. These cells are responsible for about half of asthma attacks and a third of COPD exacerbations. Unlike steroids such as prednisolone, which also reduces lung inflammation but can cause severe side effects, Benralizumab offers a more precise approach.
Study Results
The recent study, involving 158 high-risk patients suffering from asthma or COPD attacks, showed that Benralizumab was more effective than prednisolone in improving respiratory symptoms. The drug has the potential to lower the mortality rate linked to repeated steroid use and re-hospitalisations following severe attacks.
Patient Testimonials
Alison Spooner, a participant in the trial, shared her experience of feeling drastically different after using Benralizumab. Similarly, Geoffrey Pointing reported no side effects and improved sleep quality compared to steroid treatments.
Challenges in India
In India, the high cost of Benralizumab poses a major challenge, making it unaffordable for many. Further trials will be required to establish its efficacy and usefulness in the Indian context.
Conclusion
Benralizumab represents a significant advancement in asthma treatment, offering a more targeted approach with potentially fewer side effects. While the drug shows immense promise, further studies are needed to confirm its benefits and safety, especially in different regions like India.
FAQs
- What is Benralizumab?
- How does Benralizumab work?
- What were the results of the recent study?
- Are there any side effects of Benralizumab?
- Is Benralizumab ready for general use?
- What are the challenges in India regarding Benralizumab?
Benralizumab is a new treatment for asthma attacks and COPD that targets eosinophils, white blood cells linked to lung inflammation.
Benralizumab works by specifically targeting eosinophils in the lungs, reducing inflammation and improving respiratory symptoms.
The study showed that Benralizumab was more effective than prednisolone in treating asthma and COPD attacks, leading to improved quality of life for patients.
Patients in the trial reported fewer side effects compared to traditional steroid treatments, with improved sleep quality and overall well-being.
While the drug shows promise, further trials are needed to confirm its efficacy and safety. Patients should follow their doctor’s advice regarding its use.
The high cost of Benralizumab poses a challenge in India, making it inaccessible to many. Further studies are needed to assess its usefulness in the Indian healthcare system.
Tags:
Asthma, COPD, Benralizumab, Lung Health, Asthma Treatment